Market News

Chembio Diagnostics, Inc. (CEMI) Analysts See $-0.12 EPS; Great Point Partners Lowered Its Alnylam Pharmaceuticals (Put) (ALNY) Stake

Analysts expect Chembio Diagnostics, Inc. (NASDAQ:CEMI) to report $-0.12 EPS on March, 6.They anticipate $0.09 EPS change or 42.86% from last quarter’s $-0.21 EPS. After having $-0.05 EPS previously, Chembio Diagnostics, Inc.’s analysts see 140.00% EPS growth. The stock decreased 1.30% or $0.1 during the last trading session, reaching $7.6. About 69,078 shares traded. Chembio Diagnostics, Inc. (NASDAQ:CEMI) has declined 22.25% since February 20, 2017 and is downtrending. It has underperformed by 38.95% the S&P500.

Great Point Partners Llc decreased Alnylam Pharmaceuticals Inc (Put) (ALNY) stake by 9.68% reported in 2017Q3 SEC filing. Great Point Partners Llc sold 26,800 shares as Alnylam Pharmaceuticals Inc (Put) (ALNY)’s stock rose 48.45%. The Great Point Partners Llc holds 250,000 shares with $29.37 million value, down from 276,800 last quarter. Alnylam Pharmaceuticals Inc (Put) now has $12.25 billion valuation. The stock increased 0.94% or $1.14 during the last trading session, reaching $122.88. About 653,512 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since February 20, 2017 and is uptrending. It has outperformed by 16.84% the S&P500.

Chembio Diagnostics, Inc., together with its subsidiary, Chembio Diagnostic Systems, Inc., develops, makes, markets, and licenses rapid point-of-care diagnostic tests that detect infectious diseases. The company has market cap of $107.74 million. It offers rapid tests for the detection of HIV and syphilis antibodies. It currently has negative earnings. The company's products include lateral flow rapid HIV tests and Dual Path Platform (DPP) HIV 1/2 Assay Test, which detect antibodies to HIV 1 and 2 with visually interpreted results; a DPP HIV-Syphilis multiplex test for the detection of antibodies to HIV and syphilis; and a test for the detection of Hepatitis-C.

Since September 20, 2017, it had 0 buys, and 3 sales for $23.18 million activity. Greene Barry E also sold $7.68M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares. Mason Michael also sold $4.84M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Thursday, January 4.

Among 23 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 5 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals had 97 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Overweight” rating by Barclays Capital on Wednesday, November 8. The company was maintained on Friday, August 5 by JP Morgan. BMO Capital Markets maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Friday, September 22. BMO Capital Markets has “Outperform” rating and $134 target. The firm has “Buy” rating given on Thursday, November 9 by J.P. Morgan. The firm has “Overweight” rating by JP Morgan given on Thursday, November 9. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Buy” rating given on Monday, July 10 by Needham. On Thursday, September 21 the stock rating was maintained by Bernstein with “Buy”. Leerink Swann maintained the shares of ALNY in report on Thursday, January 25 with “Market Perform” rating. The rating was maintained by FBR Capital with “Buy” on Friday, January 19. The firm has “Buy” rating by Jefferies given on Thursday, August 24.

Investors sentiment decreased to 0.92 in Q3 2017. Its down 0.60, from 1.52 in 2017Q2. It dived, as 30 investors sold ALNY shares while 73 reduced holdings. 40 funds opened positions while 55 raised stakes. 86.02 million shares or 0.72% more from 85.40 million shares in 2017Q2 were reported. Atika Capital Limited Liability Company stated it has 0.84% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). The New York-based Gilder Gagnon Howe Ltd Liability has invested 1.85% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Security Savings Bank Of So Dak holds 0.28% or 2,100 shares in its portfolio. Goldman Sachs Group Inc has invested 0.05% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Boston Private Wealth Limited Com, Massachusetts-based fund reported 2,105 shares. The Luxembourg-based Artal Group Inc Sa has invested 0.51% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). First Trust Advsrs Limited Partnership has invested 0.24% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Teacher Retirement System Of Texas reported 6,748 shares. Mitsubishi Ufj & Banking owns 0.06% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 278,347 shares. Arrowstreet Cap Ltd Partnership holds 0.02% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 51,485 shares. Wells Fargo And Mn invested in 0% or 135,318 shares. Moreover, Gotham Asset Mngmt Lc has 0% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Comerica Bancorp reported 15,885 shares. Rhumbline Advisers holds 92,568 shares. Nationwide Fund Advsrs has 7,964 shares for 0% of their portfolio.

Leave a Reply

Your email address will not be published. Required fields are marked *